LIVE; Psychedelics & Pain Association (PPA) website and FREE open coursework for clinicians & practitioners

After years of planning and months of production on our project. the Psychedelics & Pain Association’s (PPA) has launched our website and FREE open coursework for clinicians and practitioners, “Introduction to Psychedelics for Chronic Pain”, with hours of presentations from the world’s leading researchers.

Panelists on our coursework include:
Dr. Joel Castellanos, Assoc. Dir. from PHRI at UCSD
Prof. Jan Ramaekers, Head of Psychophamacology at Maastricht University
Dr.Emmanuelle Schindler, MD, Ph.D., Medical Dir. Headache Center for Excellence: Connecticut VA and Yale School of Medicine
Dr. Boris Heifets, Asst. Professor at Standford University
Dr. Devon Christie, VIU and Medical Dir. at Numinus
Dr. Charles Nichols, professor at LSU and the Nichols Lab
Dr. Natasha Mason, Asst. professor at Maastricht University
James B. Close, Pain physiotherapist, co-PI and Ph.D. Candidate at Centre for Psychedelic Research, Imperial College
Julia Bornemann, neuroscience specialist, co-PI and Ph.D. Candidate at Centre for Psychedelic Research, Imperial College
C.J. Spotswood, Psychiatric Nurse Practitioner, author of “The Microdosing Guidebook”

The PPA website features a
LIVE searchable research database of all known academic papers on psychedelics and pain, autoimmune, and inflammatory conditions, updated as new ones are published and previous research is discovered.

Mechanisms of action, conditions showing strong signal, models for both pain and psychedelics are covered throughout the site, with citations.

The PPA is a collaborative project formed by
Clusterbusters, Psychedelics Today, and , who's primary goals are to advance science and public awareness around psychedelics and chronic pain.

Please watch our webisode on Psychedelics Today’s YouTube channel for an overview of our mission and offerings to both clinicians & practitioners, as well as the pain communities and broader public:

Previous
Previous

MDMA/Psilocybin treatment for Long-COVID wins first place

Next
Next

Supporting research continuing to emerge